Literature DB >> 8349785

Oxidatively modified low density lipoprotein is a chemoattractant for human T lymphocytes.

H F McMurray1, S Parthasarathy, D Steinberg.   

Abstract

Oxidatively modified low density lipoprotein (Ox-LDL) is a known chemoattractant for monocytes. Here we demonstrate, using a modified Boyden chamber assay, that human peripheral blood T lymphocytes, but not B lymphocytes, also respond chemotactically to Ox-LDL, showing a threefold increase over control and an optimum response at 10 micrograms/ml. Copper and endothelial cell-oxidized LDL and beta-VLDL were used and gave similar results. The activity was not chemokinetic and native LDL possessed no chemoattractant activity. The chemoattractant activity was found to reside in the lipid fraction of Ox-LDL. Lysophosphatidylcholine is a major phospholipid component of Ox-LDL and is known to be chemotactic for monocytes. We show that lysophosphatidylcholine is also chemotactic for T lymphocytes with a maximal fourfold increase at 10 microM. Nonmetabolizable analogues of lysophosphatidylcholine had no such chemotactic effect. Thus, Ox-LDL, by virtue of its lysophosphatidylcholine content, may contribute to the recruitment of both T lymphocytes and monocytes into developing atherosclerotic lesions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8349785      PMCID: PMC294941          DOI: 10.1172/JCI116605

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  38 in total

1.  Changes in the endothelium of the aorta and the behaviour of macrophages in experimental atheroma of rabbits.

Authors:  J C POOLE; H W FLOREY
Journal:  J Pathol Bacteriol       Date:  1958-04

2.  Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis.

Authors:  M T Quinn; S Parthasarathy; L G Fong; D Steinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

3.  Detection of activated T lymphocytes in the human atherosclerotic plaque.

Authors:  G K Hansson; J Holm; L Jonasson
Journal:  Am J Pathol       Date:  1989-07       Impact factor: 4.307

4.  T lymphocyte motility toward IL-1 in patients with interstitial lung diseases.

Authors: 
Journal:  Bull Chest Dis Res Inst Kyoto Univ       Date:  1990-03

5.  Inhibition by probucol of interleukin 1 secretion and its implication in atherosclerosis.

Authors:  G Ku; N S Doherty; J A Wolos; R L Jackson
Journal:  Am J Cardiol       Date:  1988-07-25       Impact factor: 2.778

6.  Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells.

Authors:  N Kume; M I Cybulsky; M A Gimbrone
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

7.  Interleukin-4 is chemotactic for mouse macrophages.

Authors:  A A Hiester; D R Metcalf; P A Campbell
Journal:  Cell Immunol       Date:  1992-01       Impact factor: 4.868

8.  Endothelial cell-derived chemotactic activity for mouse peritoneal macrophages and the effects of modified forms of low density lipoprotein.

Authors:  M T Quinn; S Parthasarathy; D Steinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

9.  Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque.

Authors:  L Jonasson; J Holm; O Skalli; G Bondjers; G K Hansson
Journal:  Arteriosclerosis       Date:  1986 Mar-Apr

10.  Lysophosphatidylcholine concentrations and metabolism in aortic intima plus inner media: effect of nutritionally induced atherosclerosis.

Authors:  O W Portman; M Alexander
Journal:  J Lipid Res       Date:  1969-03       Impact factor: 5.922

View more
  40 in total

1.  Cardiolipin is a normal component of human plasma lipoproteins.

Authors:  H Deguchi; J A Fernandez; T M Hackeng; C L Banka; J H Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

Review 2.  Antiinflammatory and immunomodulatory properties of statins.

Authors:  Ora Shovman; Yair Levy; Boris Gilburd; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

3.  Clinical significance of enzymatic lysophosphatidylcholine (LPC) assay data in patients with sepsis.

Authors:  W H Cho; T Park; Y Y Park; J W Huh; C-M Lim; Y Koh; D-K Song; S-B Hong
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-12-14       Impact factor: 3.267

4.  Pretreatment with quercetin prevents changes in lymphocytes E-NTPDase/E-ADA activities and cytokines secretion in hyperlipidemic rats.

Authors:  Josiane B S Braun; Jader B Ruchel; Alessandra G Manzoni; Fátima H Abdalla; Emerson A Casalli; Lívia G Castilhos; Daniela F Passos; Daniela B R Leal
Journal:  Mol Cell Biochem       Date:  2017-11-29       Impact factor: 3.396

Review 5.  Human neutrophil peptides: a novel potential mediator of inflammatory cardiovascular diseases.

Authors:  Kieran Quinn; Melanie Henriques; Tom Parker; Arthur S Slutsky; Haibo Zhang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-09-19       Impact factor: 4.733

6.  Mildly oxidized low-density lipoproteins suppress the proliferation of activated CD4+ T-lymphocytes and their interleukin 2 receptor expression in vitro.

Authors:  S Caspar-Bauguil; M Saadawi; A Negre-Salvayre; M Thomsen; R Salvayre; H Benoist
Journal:  Biochem J       Date:  1998-03-01       Impact factor: 3.857

7.  Stimulatory and inhibitory actions of lysophosphatidylcholine, depending on its fatty acid residue, on the phospholipase C/Ca2+ system in HL-60 leukaemia cells.

Authors:  F Okajima; K Sato; H Tomura; A Kuwabara; H Nochi; K Tamoto; Y Kondo; Y Tokumitsu; M Ui
Journal:  Biochem J       Date:  1998-12-01       Impact factor: 3.857

Review 8.  Immunogenic oxidized low-density lipoprotein/beta2-glycoprotein I complexes in the diagnostic management of atherosclerosis.

Authors:  Luis R Lopez; Kazuko Kobayashi; Yukana Matsunami; Eiji Matsuura
Journal:  Clin Rev Allergy Immunol       Date:  2009-08       Impact factor: 8.667

Review 9.  Why are low-density lipoproteins atherogenic?

Authors:  S G Young; S Parthasarathy
Journal:  West J Med       Date:  1994-02

10.  Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins.

Authors:  S Hörkkö; D A Bird; E Miller; H Itabe; N Leitinger; G Subbanagounder; J A Berliner; P Friedman; E A Dennis; L K Curtiss; W Palinski; J L Witztum
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.